JP2007522229A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007522229A5 JP2007522229A5 JP2006553251A JP2006553251A JP2007522229A5 JP 2007522229 A5 JP2007522229 A5 JP 2007522229A5 JP 2006553251 A JP2006553251 A JP 2006553251A JP 2006553251 A JP2006553251 A JP 2006553251A JP 2007522229 A5 JP2007522229 A5 JP 2007522229A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- factor
- binding fragment
- human factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003712 Complement Factor B Human genes 0.000 claims 35
- 108090000056 Complement Factor B Proteins 0.000 claims 35
- 102000004965 antibodies Human genes 0.000 claims 32
- 108090001123 antibodies Proteins 0.000 claims 32
- 239000000427 antigen Substances 0.000 claims 27
- 102000038129 antigens Human genes 0.000 claims 27
- 108091007172 antigens Proteins 0.000 claims 27
- 239000003814 drug Substances 0.000 claims 6
- 102000005614 monoclonal antibodies Human genes 0.000 claims 5
- 108010045030 monoclonal antibodies Proteins 0.000 claims 5
- 208000006673 Asthma Diseases 0.000 claims 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 4
- 201000005794 allergic hypersensitivity disease Diseases 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 238000005755 formation reaction Methods 0.000 claims 4
- 230000009610 hypersensitivity Effects 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 3
- 230000000295 complement Effects 0.000 claims 3
- 201000009910 diseases by infectious agent Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 230000001629 suppression Effects 0.000 claims 3
- 241000709661 Enterovirus Species 0.000 claims 2
- 241000283086 Equidae Species 0.000 claims 2
- 241000699670 Mus sp. Species 0.000 claims 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 241000700159 Rattus Species 0.000 claims 2
- 241000282887 Suidae Species 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 230000001225 therapeutic Effects 0.000 claims 2
- 208000010370 Adenoviridae Infections Diseases 0.000 claims 1
- 206010060931 Adenovirus infection Diseases 0.000 claims 1
- 208000006778 Allergic Bronchopulmonary Aspergillosis Diseases 0.000 claims 1
- 206010052613 Allergic bronchitis Diseases 0.000 claims 1
- 206010003557 Asthma exercise induced Diseases 0.000 claims 1
- 206010006451 Bronchitis Diseases 0.000 claims 1
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000004657 Exercise-Induced Asthma Diseases 0.000 claims 1
- 230000035693 Fab Effects 0.000 claims 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 claims 1
- 208000006897 Interstitial Lung Disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229940071648 Metered Dose Inhaler Drugs 0.000 claims 1
- 208000007892 Occupational Asthma Diseases 0.000 claims 1
- 208000002216 Parasitic Lung Disease Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010039083 Rhinitis Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 238000004166 bioassay Methods 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000002860 competitive Effects 0.000 claims 1
- 230000000875 corresponding Effects 0.000 claims 1
- 201000003883 cystic fibrosis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000009580 eosinophilic pneumonia Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
Claims (24)
- Ｂ因子の第３の短コンセンサスリピート（ＳＣＲ）ドメインに選択的に結合してＣ３ｂＢｂ複合体の形成を抑制する、単離された抗体もしくはその抗原結合性フラグメント。
- Ｂ因子に結合してＤ因子によるＢ因子の開裂を抑制もしくは阻害する請求項１に記載の単離された抗体もしくはその抗原結合性フラグメント。
- ヒトＢ因子の第３の短コンセンサスリピート（ＳＣＲ）ドメインに結合する請求項１に記載の単離された抗体もしくはその抗原結合性フラグメント。
- ａ）およその位置Ｔｙｒ１３９からおよその位置Ｓｅｒ１８５まで、もしくはそれに相当する非ヒトＢ因子配列内の位置を含むヒトＢ因子（配列番号２）の少なくとも一部を含有するＢ因子のエピトープと、
ｂ）およその位置Ｔｙｒ１３９からおよその位置Ｓｅｒ１４１まで、もしくはそれに相当する非ヒトＢ因子配列内の位置を含むヒトＢ因子（配列番号２）の少なくとも一部を含有するＢ因子のエピトープと、
ｃ）およその位置Ｇｌｕ１８２からおよその位置Ｓｅｒ１８５まで、もしくはそれに相当する非ヒトＢ因子配列内の位置を含むヒトＢ因子（配列番号２）の少なくとも一部を含有するＢ因子のエピトープと、
ｄ）非ヒトＢ因子配列内の、Ｔｙｒｌ３９，Ｃｙｓ１４０，Ｓｅｒｌ４１，Ｇ１ｕ１８２，Ｇｌｙｌ８４，またはＳｅｒｌ８５の位置の一つもしくはそれ以上の位置、もしくはそれらに相当する位置を含むヒトＢ因子（配列番号２）の少なくとも一部を含有するＢ因子のエピトープと
からなる群から選択されるＢ因子の第３のＳＣＲドメイン内のエピトープに選択的に結合する請求項１に記載の単離された抗体もしくはその抗原結合性フラグメント。 - 複数種の哺乳類由来のＢ因子に選択的に結合する請求項１の単離された抗体もしくはその抗原結合性フラグメント。
- ヒト由来のＢ因子と、非ヒト霊長類、マウス、ラット、ブタ、ウマ及びウサギからなる群から選択される動物由来のＢ因子とに選択的に結合する請求項１に記載の単離された抗体もしくはその抗原結合性フラグメント。
- 前記抗体がモノクローナル抗体１３７９（ＡＴＣＣ Ｄｅｐｏｓｉｔ社製、Ｎｏ．ＰＴＡ−６２３０）である請求項１に記載の単離された抗体もしくはその抗原結合性フラグメント。
- 複数種の哺乳類由来のＢ因子に選択的に結合してＣ３ｂＢｂ複合体の形成を抑制する、単離された抗体もしくはその抗原結合性フラグメント。
- ヒト由来のＢ因子と、非ヒト霊長類、マウス、ラット、ブタ、ウマ及びウサギからなる群から選択される動物由来のＢ因子とに選択的に結合する請求項１または請求項８に記載の単離された抗体もしくはその抗原結合性フラグメント。
- 前記抗体が非補体活性化アイソタイプもしくはサブクラスである請求項１または請求項８に記載の単離された抗体もしくはその抗原結合性フラグメント。
- 前記抗体が、モノクローナル抗体、ヒト化抗体、二重特異性抗体、および一価抗体からなる群から選択される請求項１または請求項８に記載の単離された抗体もしくはその抗原結合性フラグメント。
- 前記抗原結合性フラグメントがＦａｂフラグメントである請求項１または請求項８に記載の単離された抗体もしくはその抗原結合性フラグメント。
- Ｂ因子に選択的に結合する、単離された抗体もしくはその抗原結合性フラグメントであって、モノクローナル抗体１３７９（ＡＴＣＣ Ｄｅｐｏｓｉｔ社製、Ｎｏ．ＰＴＡ−６２３０）のヒトＢ因子への特異的な結合を競合阻害し、前記抗体もしくはその抗原結合性フラグメントがヒトＢ因子に結合した場合には、補体第二経路活性を阻害するモノクローナル抗体１３７９の機能が阻害される、単離された抗体もしくはその抗原結合性フラグメント。
- モノクローナル抗体１３７９のヒトＢ因子への結合を競合阻害し、ヒトＢ因子の存在下で競合結合する特異性が抗体―抗体競合アッセイによって確認されている請求項１３に記載の抗体もしくはその抗原結合性フラグメント。
- ヒトＢ因子に選択的に結合する、単離された抗体もしくは抗原結合性フラグメントであって、該単離された抗体もしくは抗原結合性フラグメントが第二抗体もしくはその抗原結合性フラグメントのヒトＢ因子への特異的な結合を競合阻害し、前期第二抗体もしくはその抗原結合性フラグメントがヒトＢ因子の第３のＳＣＲドメインに結合する、単離された抗体もしくは抗原結合性フラグメント。
- 請求項１から１５のいずれか一項に記載の単離された抗体もしくはその抗原結合性フラグメントを含む組成物。
- Ｂ因子の短コンセンサスリピート（ＳＣＲ）ドメインに選択的に結合してＣ３ｂＢｂ複合体の形成を抑制する抗原結合性ポリペプチド。
- 複数種の哺乳類由来のＢ因子に選択的に結合してＣ３ｂＢｂ複合体の形成を抑制する抗原結合性ポリペプチド。
- 動物の気道過敏性（ＡＨＲ）もしくは気道炎症を低減もしくは抑制するための治療薬であって、請求項１から１５のいずれか一項に記載の抗体もしくはその抗原結合性フラグメント、または請求項１７もしくは請求項１８に記載の抗体結合性ポリペプチドを含有する治療薬。
- 乾燥して分散可能な粉末、無水エタノール、小カプセル、リポソーム、噴霧化スプレー、および注射可能な賦形剤からなる群から選択される、薬学的に許容可能な担体を更に含有する請求項１９に記載の治療薬。
- 無水エタノール、乾燥粉末吸入システム、超音波吸入システム、加圧計量式吸入器、および計量式溶液装置からなる群から選択される担体または装置で投与されるように構成されている請求項１９に記載の治療薬。
- 前記気道過敏性もしくは気道炎症は、喘息、慢性閉塞性肺疾患（ＣＯＰＤ）、アレルギー性気管支肺アスペルギルス症、過敏性肺炎、好酸球性肺炎、気腫、気管支炎、アレルギー性気管支炎気管支拡張症、嚢泡性線維症、結核、過敏性肺炎、職業性喘息、サルコイド、反応性気道疾患症候群、間質性肺疾患、好酸球増多症候群、鼻炎、副鼻腔炎、運動誘発喘息、汚染誘発喘息、咳喘息、寄生虫性肺疾患、ＲＳウイルス（ＲＳＶ）感染症、パラインフルエンザウイルス（ＰＩＶ）感染症、ライノウイルス（ＲＶ）感染症、およびアデノウイルス感染症からなる群から選択される疾病を伴う請求項１９に記載の治療薬。
- 動物の気道過敏性（ＡＨＲ）もしくは気道炎症を低減もしくは抑制するための治療薬であって、動物の補体第二経路活性化を選択的に阻害するように構成されている治療薬。
- 動物の虚血―再かん流障害を低減もしくは抑制するための治療薬であって、請求項１から１５のいずれか一項に記載の抗体もしくは抗原結合性フラグメント、または請求項１７もしくは１８に記載の抗体結合性ポリペプチドを含有する治療薬。
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54359404P | 2004-02-10 | 2004-02-10 | |
| US60/543,594 | 2004-02-10 | ||
| USPCT/US2004/015040 | 2004-05-13 | ||
| PCT/US2004/015040 WO2004103288A2 (en) | 2003-05-13 | 2004-05-13 | Method of preventing recurrent miscarriages |
| US63623904P | 2004-12-14 | 2004-12-14 | |
| US60/636,239 | 2004-12-14 | ||
| PCT/US2005/004346 WO2005077417A1 (en) | 2004-02-10 | 2005-02-10 | Inhibition of factor b, the alternative complement pathway and methods related thereto |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007522229A JP2007522229A (ja) | 2007-08-09 |
| JP2007522229A5 true JP2007522229A5 (ja) | 2008-04-03 |
| JP5137053B2 JP5137053B2 (ja) | 2013-02-06 |
Family
ID=38007673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006553251A Expired - Fee Related JP5137053B2 (ja) | 2004-02-10 | 2005-02-10 | 抗ｂ因子抗体もしくはその抗原結合性フラグメント、それを含む組成物、抗原結合性ポリペプチド、および治療薬 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US7999082B2 (ja) |
| JP (1) | JP5137053B2 (ja) |
| BR (1) | BRPI0506629A (ja) |
| CY (1) | CY1114558T1 (ja) |
| DK (1) | DK1713503T3 (ja) |
| ES (1) | ES2432112T3 (ja) |
| PT (1) | PT1713503E (ja) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070123466A1 (en) * | 2003-05-13 | 2007-05-31 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Method of treating recurrent miscarriages |
| ES2432112T3 (es) * | 2004-02-10 | 2013-11-29 | The Regents Of The University Of Colorado, A Body Corporate | Inhibición del factor B, de la vía alternativa del complemento y métodos relacionados |
| US8911733B2 (en) * | 2005-05-26 | 2014-12-16 | Musc Foundation For Research Development | Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| PT2044111E (pt) | 2006-06-21 | 2014-11-12 | Univ Colorado Regents | Abordagem seletiva do fator h do complemento para o tratamento de doenças |
| WO2008097525A2 (en) | 2007-02-05 | 2008-08-14 | Potentia Pharmaceuticals, Inc. | Local complement inhibition for treatment of complement-mediated disorders |
| KR20090122465A (ko) * | 2007-03-01 | 2009-11-30 | 어드벤스드 비젼 테라피스, 인코포레이티드 | 염증성 질환의 치료 |
| EP2236518B1 (en) * | 2007-03-14 | 2014-08-06 | Alexion Cambridge Corporation | Humaneered anti-factor B antibody |
| JP2011503094A (ja) * | 2007-11-08 | 2011-01-27 | ジェネンテック， インコーポレイテッド | 抗ｂ因子抗体およびそれらの使用 |
| JP5112948B2 (ja) * | 2008-05-15 | 2013-01-09 | 凸版印刷株式会社 | 着色アルカリ現像型感光性樹脂組成物、それを用いたカラーフィルタ並びに液晶分割配向制御用突起付き基板及び該基板を備えた液晶表示装置 |
| US20090324585A1 (en) * | 2008-06-12 | 2009-12-31 | The Trustees of the Leland Standford Junior University | Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis |
| US20110160636A1 (en) * | 2008-09-10 | 2011-06-30 | Rekha Bansal | Device and method for inhibiting complement activation |
| GB0904214D0 (en) * | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
| AU2010266127B2 (en) | 2009-07-02 | 2015-11-05 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
| KR20120130748A (ko) | 2009-11-05 | 2012-12-03 | 알렉시온 캠브리지 코포레이션 | 발작성 야간 혈색소뇨증, 용혈성 빈혈, 및 혈관내 및 혈관외 용혈을 수반한 질환 상태의 치료 |
| EP2569332B1 (en) | 2010-05-14 | 2019-01-09 | The Regents of the University of Colorado, A Body Corporate | Improved complement receptor 2 (cr2) targeting groups |
| CA2803588A1 (en) | 2010-06-22 | 2011-12-29 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the c3d fragment of complement component 3 |
| JP6618682B2 (ja) | 2011-06-22 | 2019-12-11 | アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 補体阻害剤による慢性障害の治療方法 |
| US8691513B2 (en) | 2011-06-23 | 2014-04-08 | Quidel Corporation | Methods of use for an immunoassay detecting fragment Ba |
| US9243070B2 (en) | 2012-04-03 | 2016-01-26 | Novelmed Therapeutics, Inc. | Humanized and chimeric anti-factor Bb antibodies and uses thereof |
| EP2855529A4 (en) | 2012-05-24 | 2015-12-09 | Alexion Pharma Inc | HUMANIZED ANTI-FACTOR B ANTIBODIES |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| AU2013302441B2 (en) | 2012-08-17 | 2018-05-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
| DK2920201T3 (da) | 2012-11-15 | 2020-04-14 | Apellis Pharmaceuticals Inc | Langtidsvirkende compstatin-analoger og relaterede sammensætninger og fremgangsmåder |
| WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| CN105683759B (zh) | 2013-08-07 | 2019-03-29 | 瑞颂医药公司 | 非典型溶血性尿毒综合征(aHUS)生物标志物蛋白 |
| HUE045109T2 (hu) | 2013-09-13 | 2019-12-30 | Ionis Pharmaceuticals Inc | A B-komplementfaktor modulátorai |
| KR20160118368A (ko) | 2014-02-25 | 2016-10-11 | 아칠리온 파르마세우티칼스 인코포레이티드 | 보체 매개된 장애의 치료를 위한 에터 화합물 |
| US9796776B2 (en) | 2014-02-27 | 2017-10-24 | Allergan, Inc. | Complement factor Bb antibodies |
| AU2015256299C1 (en) | 2014-05-05 | 2022-01-06 | Regeneron Pharmaceuticals, Inc. | Humanized C5 and C3 animals |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| EP3340982B1 (en) | 2015-08-26 | 2021-12-15 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
| AR105809A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos médicos |
| WO2017035357A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of medical disorders |
| WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| AR105808A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos de amida para el tratamiento de trastornos médicos |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017035355A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Ether compounds for treatment of medical disorders |
| WO2017035362A1 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses |
| WO2017035361A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for the treatment of medical disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| WO2017035351A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of medical disorders |
| EP3359555B1 (en) | 2015-10-07 | 2023-12-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens |
| AU2017210042B2 (en) | 2016-01-20 | 2021-01-21 | 396419 B.C. Ltd. | Compositions and methods for inhibiting Factor D |
| EP3526248A4 (en) | 2016-10-17 | 2020-07-08 | Musc Foundation for Research Development | COMPOSITIONS AND METHODS FOR TREATING LESIONS OF THE CENTRAL VENEER SYSTEM |
| WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| ES2933513T3 (es) | 2017-03-01 | 2023-02-09 | Achillion Pharmaceuticals Inc | Compuestos macrocíclicos para el tratamiento de trastornos médicos |
| CA3053818A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
| BR112019020955A2 (pt) | 2017-04-07 | 2020-05-05 | Apellis Pharmaceuticals Inc | regimes de dosagem e composições e métodos relacionados |
| EP3847174A4 (en) | 2018-09-06 | 2022-06-15 | Achillion Pharmaceuticals, Inc. | MORPHIC FORMS OF COMPLEMENT D FACTOR INHIBITORS |
| JP7443375B2 (ja) | 2018-09-06 | 2024-03-05 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 医学的障害の治療のための大環状化合物 |
| CA3114039A1 (en) | 2018-09-25 | 2020-04-02 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
| WO2021067526A1 (en) | 2019-10-02 | 2021-04-08 | Alexion Pharmaceuticals, Inc. | Complement inhibitors for treating drug-induced complement-mediated response |
| CN115243724A (zh) | 2020-02-19 | 2022-10-25 | 纳米医疗有限公司 | 可用于治疗癌症的经调配和/或共调配的含有TFGβ拮抗剂前药的脂质体组合物和其方法 |
| US20230349887A1 (en) | 2020-05-15 | 2023-11-02 | Alexion Pharmaceuticals, Inc. | Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease |
| EP4348263A1 (en) | 2021-05-28 | 2024-04-10 | Alexion Pharmaceuticals, Inc. | Methods for detecting cm-tma biomarkers |
| WO2023212664A1 (en) * | 2022-04-27 | 2023-11-02 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Synapse surgery tools and associated methods for neural circuit-specific synapse ablation and modification |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4845083A (en) * | 1983-10-05 | 1989-07-04 | Merck Frosst Canada, Inc. | Method of inhibiting mammalian leukotriene biosynthesis |
| JPH0742235B2 (ja) * | 1985-11-08 | 1995-05-10 | 三共株式会社 | 自己免疫性疾病の予防・治療剤 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US6458360B1 (en) * | 1990-04-25 | 2002-10-01 | The Johns Hopkins University | Soluble complement regulatory molecules |
| EP0512733A2 (en) * | 1991-05-03 | 1992-11-11 | Washington University | Modified complement system regulator |
| DE4222534A1 (de) | 1992-07-09 | 1994-01-13 | Behringwerke Ag | Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura |
| US5976540A (en) * | 1993-05-17 | 1999-11-02 | T Cell Sciences, Inc. | Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions |
| US5679546A (en) * | 1993-09-24 | 1997-10-21 | Cytomed, Inc. | Chimeric proteins which block complement activation |
| US5869615A (en) | 1994-01-03 | 1999-02-09 | Washington University | Modified complement proteases |
| US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
| US6030917A (en) * | 1996-07-23 | 2000-02-29 | Symyx Technologies, Inc. | Combinatorial synthesis and analysis of organometallic compounds and catalysts |
| US6165463A (en) * | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| GB9624731D0 (en) * | 1996-11-28 | 1997-01-15 | Univ Leicester | Complement inhibitor |
| DE69835524T2 (de) * | 1997-08-26 | 2007-04-05 | Amgen Fremont Inc. | Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg |
| US8088386B2 (en) * | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
| KR100425965B1 (ko) | 1998-02-20 | 2004-04-06 | 타녹스 인코퍼레이티드 | 보체 활성화의 억제물질 |
| US6956107B2 (en) * | 1998-02-20 | 2005-10-18 | Tanox, Inc. | Inhibitors of complement activation |
| AU1705100A (en) | 1998-10-09 | 2000-05-01 | Musc Foundation For Research Development | Blocking factor b to treat complement-mediated immune disease |
| GB9930659D0 (en) | 1999-12-24 | 2000-02-16 | Bio Discovery Ltd | Inhibitors of complement activation |
| DE60136272D1 (de) * | 2000-04-29 | 2008-12-04 | Univ Iowa Res Found | Diagnostika und therapeutika für makula degeneration erkrankungen |
| US6820011B2 (en) * | 2001-04-11 | 2004-11-16 | The Regents Of The University Of Colorado | Three-dimensional structure of complement receptor type 2 and uses thereof |
| CA2480082A1 (en) * | 2002-03-29 | 2003-10-16 | Neurogen Corporation | Combination therapy for the treatment of conditions with pathogenic inflammatory components |
| US7538195B2 (en) * | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| JP4601426B2 (ja) | 2002-09-06 | 2010-12-22 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体成分ｃ５に対する抗体を使用する喘息の処置の方法 |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| US7541440B2 (en) * | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
| AU2003271681A1 (en) | 2002-10-04 | 2004-04-23 | Sanquin Blood Supply Foundation Amsterdam | Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation |
| JP4915980B2 (ja) * | 2002-11-15 | 2012-04-11 | エムユーエスシー ファウンデーション フォー リサーチ デベロップメント | 補体レセプター２標的化補体調節因子 |
| US20070065433A1 (en) * | 2003-02-21 | 2007-03-22 | Mollnes Tom E | Methods and compositions for the treatment of meconium aspiration syndrome |
| US20070123466A1 (en) | 2003-05-13 | 2007-05-31 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Method of treating recurrent miscarriages |
| BRPI0410876B8 (pt) | 2003-06-02 | 2023-01-24 | Evolutec Ltd | composição, proteína de fusão, molécula de cdna, vetor, célula hospedeira procariótica recombinante, método para preparar uma molécula inibidora do complemento, e, usos de uma composição e de uma proteína de fusão |
| WO2005003159A1 (en) | 2003-07-03 | 2005-01-13 | Koeln Johanna | Complement depletion using recombinant human c3-derivatives |
| US7638481B2 (en) | 2003-09-05 | 2009-12-29 | University Of Louisville Research Foundation, Inc. | Treatment of spinal cord injury |
| US7959919B2 (en) | 2003-11-19 | 2011-06-14 | Novelmed Therapeutics, Inc. | Method of inhibiting factor B-mediated complement activation |
| US6976540B2 (en) * | 2003-12-12 | 2005-12-20 | Varco I/P, Inc. | Method and apparatus for offline standbuilding |
| JP4782700B2 (ja) * | 2004-01-20 | 2011-09-28 | カロバイオス ファーマシューティカルズ インコーポレイティッド | 最低限必須な結合決定基を用いた抗体特異性の移入 |
| EP1713503B1 (en) | 2004-02-10 | 2013-07-31 | The Regents of the University of Colorado, a Body Corporate | Inhibition of factor b, the alternative complement pathway and methods related thereto |
| ES2432112T3 (es) | 2004-02-10 | 2013-11-29 | The Regents Of The University Of Colorado, A Body Corporate | Inhibición del factor B, de la vía alternativa del complemento y métodos relacionados |
| US20090004183A1 (en) | 2004-07-23 | 2009-01-01 | Taylor Ronald P | Compositions and Methods for Regulating the Alternative Pathway of Complement |
| AU2005334481A1 (en) | 2004-08-11 | 2007-01-25 | Trubion Pharmaceuticals, Inc. | Binding domain fusion proteins |
| RU2007119382A (ru) | 2004-10-25 | 2008-11-27 | Мерк энд Ко., Инк. (US) | Антитела против addl и их применение |
| ES2429541T3 (es) * | 2004-11-16 | 2013-11-15 | Kalobios Pharmaceuticals, Inc. | Intercambio de casete de región variable de inmunoglobulina |
| JP2008520242A (ja) | 2004-11-18 | 2008-06-19 | イェール ユニバーシティ | 視覚障害を処置するための方法および組成物 |
| AU2006211625A1 (en) | 2005-01-14 | 2006-08-10 | The Regents Of The University Of California | Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders |
| US7745389B2 (en) * | 2005-02-14 | 2010-06-29 | University Of Iowa Research Foundation | Methods for treatment of age-related macular degeneration |
| US8911733B2 (en) * | 2005-05-26 | 2014-12-16 | Musc Foundation For Research Development | Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions |
| CN101262855A (zh) | 2005-09-08 | 2008-09-10 | 帝斯曼知识产权资产管理有限公司 | 治疗或预防年龄相关性黄斑变性的方法 |
| US20080318264A1 (en) | 2005-09-09 | 2008-12-25 | University Of Iowa Research Foundation | Biomarkers Associated With Age-Related Macular Degeneration |
| NZ567483A (en) | 2005-11-04 | 2012-04-27 | Genentech Inc | Use of complement pathway inhibitors to treat ocular diseases |
| PT2044111E (pt) * | 2006-06-21 | 2014-11-12 | Univ Colorado Regents | Abordagem seletiva do fator h do complemento para o tratamento de doenças |
| EP2236518B1 (en) | 2007-03-14 | 2014-08-06 | Alexion Cambridge Corporation | Humaneered anti-factor B antibody |
| PE20090329A1 (es) * | 2007-05-30 | 2009-03-27 | Abbott Lab | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos |
| AU2010266127B2 (en) * | 2009-07-02 | 2015-11-05 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
| KR20120130748A (ko) | 2009-11-05 | 2012-12-03 | 알렉시온 캠브리지 코포레이션 | 발작성 야간 혈색소뇨증, 용혈성 빈혈, 및 혈관내 및 혈관외 용혈을 수반한 질환 상태의 치료 |
| EP2569332B1 (en) | 2010-05-14 | 2019-01-09 | The Regents of the University of Colorado, A Body Corporate | Improved complement receptor 2 (cr2) targeting groups |
| CA2803588A1 (en) | 2010-06-22 | 2011-12-29 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the c3d fragment of complement component 3 |
-
2005
- 2005-02-10 ES ES05722948T patent/ES2432112T3/es active Active
- 2005-02-10 DK DK05722948.6T patent/DK1713503T3/da active
- 2005-02-10 BR BRPI0506629-8A patent/BRPI0506629A/pt not_active IP Right Cessation
- 2005-02-10 PT PT57229486T patent/PT1713503E/pt unknown
- 2005-02-10 US US11/057,047 patent/US7999082B2/en not_active Expired - Fee Related
- 2005-02-10 JP JP2006553251A patent/JP5137053B2/ja not_active Expired - Fee Related
-
2007
- 2007-08-03 US US11/888,997 patent/US8652475B2/en not_active Expired - Fee Related
- 2007-08-22 US US11/843,617 patent/US8703140B2/en not_active Expired - Fee Related
-
2013
- 2013-10-30 CY CY20131100959T patent/CY1114558T1/el unknown
-
2014
- 2014-02-18 US US14/183,213 patent/US20140154307A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007522229A5 (ja) | ||
| JP5137053B2 (ja) | 抗ｂ因子抗体もしくはその抗原結合性フラグメント、それを含む組成物、抗原結合性ポリペプチド、および治療薬 | |
| US10479828B2 (en) | Compositions comprising an anti-C5 antibody | |
| JP5872757B2 (ja) | ヒト化抗ｂ因子抗体 | |
| AU2005212369B2 (en) | Inhibition of factor B, the alternative complement pathway and methods related thereto | |
| JP2010500360A5 (ja) | ||
| US20070224204A1 (en) | Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents | |
| US9301994B2 (en) | LIGHT inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment | |
| JP2009511480A5 (ja) | ||
| WO2007049017A3 (en) | Agents that bind a target in pulmonary tissue for treating respiratory diseases | |
| JP2011006464A (ja) | 喘息の治療における抗−ＴＮＦα抗体 | |
| CN106795216A (zh) | 可用于被动流感免疫的抗体及其组合物、组合和使用方法 | |
| AU2001261137A1 (en) | Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents | |
| JP2013525310A5 (ja) | ||
| JP2008531719A5 (ja) | ||
| JP2007506681A5 (ja) | ||
| RU2006113701A (ru) | Лечение респираторных заболеваний антителами против рецептора il-2 | |
| EP3957364A1 (en) | A binding molecule specifically binding to human cd4 for use in the treatment of pulmonary diseases | |
| KR20210097756A (ko) | 폴리클로날 면역글로불린을 사용한 급성 악화를 예방하거나 치료하기 위한 방법 및 조성물 |